The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...

Recognizing the five critical signs of Alzheimer's final progression helps families understand what to expect and how to ...

Previous studies have concluded that early intervention in dementia cases can increase patients' treatment options and ...

A recent review by researchers at Philadelphia College of Osteopathic Medicine (PCOM) shows Chlamydia pneumoniae (Cpn) and ...

Study offers patients the opportunity to try an experimental, non-drug therapy for Alzheimer's using an FDA-designated Breakthrough Device ATLANTA, July ...

Cognition Therapeutics Inc. (NASDAQ:CGTX) saw its stock climb sharply by 75% following a productive end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) concerning its Alzheimer’s ...

Alzheimer’s disease is a serious condition that causes memory loss and thinking problems. While there’s no cure, research ...

Following a Mediterranean diet long-term may have weight loss benefits but it may not be enough to enhance cognitive function ...

A recent study from UCLA identifies four distinct clusters of symptoms that can progress to Alzheimer's disease, offering new ...

As Alzheimer's disease progresses, behavioral and psychiatric issues become common, distressing, and even dangerous for ...

As Alzheimer's disease progresses beyond the early stages, the behavior changes and emotional impacts of the disease can be ...

There's still so much we don't know about Alzheimer's disease, but the link between poor sleep and worsening disease is one ...